Marijuana via joint

Phase 1Small molecule

Marijuana via joint is one of 3 small molecule programs targeting Cigarette Smoking-Related Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cigarette Smoking-Related CarcinomaNot yet recruiting

Cigarette Smoking-Related CarcinomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Cigarette Smoking-Related Carcinoma

#DrugCompanyPhaseTrials

Wellbutrin

GSK

Phase 3

1 2

Marijuana via joint

RRoswell Park Cancer Institute

Phase 1

1 3

Oral Nicotine Pouches

MMedical University of South Carolina

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Cigarette Smoking-Related Carcinoma

NCT06055231

Clinical

Trials by Indication[1]

Cigarette Smoking-Related Carcinoma1 trial

A Randomized Within-Subject Cross-Over Study to Compare Short-Term PK/PD Effects of Vaping THC-containing Liquids vs. Smoked Cannabis

Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06055231·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Marijuana via joint. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Marijuana via joint compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Marijuana via joint. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRoswell Park Cancer Institute

Marijuana via joint

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Cigarette Smoking-Related Carcinoma1 trial

References

Drug Info

Quick Facts

Related News